Sparks - OSE Immunotherapeutics

OSE Immunotherapeutics has announced that its partner, Boehringer Ingelheim (BI), will present early clinical data on its SIRPα inhibitors, BI 765063 and BI 770371, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (30 May to 3 June, 2025).

BI 765063 is being evaluated in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab plus cetuximab in a Phase Ib trial and has demonstrated a desirable safety profile, as well as potentially promising early efficacy signals (preliminary signs of immune activation and additive antitumor activity) as a second-line treatment in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Next-generation SIRPα inhibitor BI 770371, both as a monotherapy and in combination with the PD1 inhibitor ezabenlimab, was previously shown to be well tolerated in a dose-escalation trial in patients with advanced solid tumours. There were no dose-limiting toxicities in either treatment arm and the maximum tolerated dose was not reached in either group. BI is evaluating the candidate in a Phase Ib study in the first-line setting for patients with R/M HNSCC.